{"id":8596,"date":"2025-08-05T04:14:35","date_gmt":"2025-08-05T08:14:35","guid":{"rendered":"https:\/\/www.packagingindustrynews.com\/?p=8596"},"modified":"2025-08-05T04:14:35","modified_gmt":"2025-08-05T08:14:35","slug":"gerresheimer-to-spin-off-moulded-glass-business","status":"publish","type":"post","link":"https:\/\/www.packagingindustrynews.com\/?p=8596","title":{"rendered":"Gerresheimer to spin off moulded glass business"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \n <\/picture>
The moulded glass division has been strengthened by the acquisition of Bormioli Pharma. Credit: Gerresheimer.<\/figcaption><\/figure>\n<\/p><\/div>\n

Gerresheimer has announced plans to separate its moulded glass business following a comprehensive strategic review aimed at assessing growth opportunities and competitive positioning.<\/p>\n

The company, which serves the pharmaceutical, biotech, and cosmetic sectors, plans to initiate a sales process for this business unit.<\/p>\n

The moulded glass division, strengthened by the acquisition of Bormioli Pharma, operates eight production facilities across the Americas, Europe, and Asia.<\/p>\n

In 2024, this unit generated approximately \u20ac735m ($850.4m) in revenues, with an adjusted earnings before interest, taxes, depreciation, and amortisation margin of around 20%.<\/p>\n

As part of the integration of Bormioli Pharma, Gerresheimer is establishing the moulded glass business as a standalone entity.<\/p>\n

Further updates on this transition will be shared during the upcoming capital markets day scheduled for 15 October 2025.<\/p>\n

The combined operations provide a diverse range of glass packaging solutions, including bottles, jars, and containers, for the pharmaceutical, cosmetic, and food and beverage sectors.<\/p>\n

In addition, the acquisition has allowed Gerresheimer to expand its offerings, including primary packaging and dosing systems for pharmaceuticals while enhancing opportunities for integrating high-value plastic solutions within the industry.<\/p>\n

Gerresheimer CEO Dietmar Siemssen said: \u201cWe see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group.<\/p>\n

\u201cAs part of our strategic transformation, Gerresheimer will focus even stronger on the portfolio of systems and solutions for the pharma and biotech industry.\u201d<\/p>\n

The company has invested around \u20ac100m in upgrading its facility in Lohr am Main, Germany, by installing an energy-efficient oxy-hybrid furnace over the past two years.<\/p>\n

In December 2024, Gerresheimer announced the addition<\/a> of a new syringe production hall at its site in Skopje, North Macedonia, with an investment of more than \u20ac100m.<\/p>\n

<\/p>\n

<\/p>\n

\n